GlycoMimetics

Health biotech drug development oncology pharma

GlycoMimetics is a clinical-stage biotechnology company. The Company uses novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.

Revenue(FY, 2016)

$18.5 K

Market capitalization(2017-09-19)

$311.6 M

Company Growth (employees)

Type

Public

Rockville, US

Founded

2003

Size (employees)

42 (est)

Website

glycomimetics.com

GlycoMimetics was founded in 2003 and is headquartered in Rockville, US

Key People at GlycoMimetics

Brian Hahn

Chief Financial Officer

John Baldwin

Director

Michael Henos

Director

Franklin H. Top

Director

William Gust

Director

M. James Barrett

Chairman of the Board of Directors

GlycoMimetics Office Locations

GlycoMimetics has an office in Rockville

Rockville, US (HQ)

9708 Medical Center Dr

GlycoMimetics Data and Metrics

GlycoMimetics Financial Metrics

GlycoMimetics's revenue was reported to be $18.5 k in FY, 2016

Summary

USD

GlycoMimetics's current market capitalization is $311.6 m.

Income Statement

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Revenue	15 m	20.1 m	18.5 k
Revenue growth, %		34%	(100%)
EBIT	(11.1 m)	(12.8 m)
EBIT margin, %	(74%)	(64%)

Quarterly

show all

Balance Sheet

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Cash	55.2 m	46.8 m	40 m
Accounts Receivable			13.6 m
Inventories	916.2 k	441.8 k	478.5 k
Current Assets	56.1 m	47.2 m	40.5 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Cash	66.2 m	61.4 m	46.6 m	40.2 m	53.8 m	38.8 m	53.1 m	45.3 m	34.6 m
Accounts Receivable				20 m
Current Assets	67.1 m	61.9 m	47.3 m	60.8 m	54.5 m	39.5 m	54.5 m	46.5 m	35.3 m
PP&E	420.6 k	481.9 k	420.4 k	579.2 k	567.2 k	491.4 k	488 k	676.6 k	1.1 m

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Net Income	(11.1 m)	(12.8 m)	(31.8 m)
Depreciation and Amortization	158.7 k	191.5 k	190.5 k
Accounts Receivable	(1.9 m)	(1.7 m)	(1.9 m)
Inventories	1.7 m	474.4 k	(36.7 k)

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Net Income	2.9 m	(3.7 m)	(7.1 m)	3.3 m	(3.9 m)	(7.6 m)	(15.6 m)	(23.5 m)	(7.9 m)
Depreciation and Amortization	73.5 k	114.3 k	44.2 k	90.5 k	142.4 k	47.2 k	93.9 k	139.7 k	54.3 k
Accounts Receivable				(20 m)
Accounts Payable	(672.7 k)	(561.2 k)	299.5 k	222.5 k	(240.9 k)	1 m	816.9 k	682.5 k	(1.1 m)